Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 18, 2026 16:05 ET | Source: TheRas, Inc. (d/b/a BBOT)

BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026

SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway...
March 18, 2026 07:00 ET | Source: Nutriband Inc.

Nutriband AI Kinesiology Tapes approved for Distribution and Sale in Costa Rica

Approval in Costa Rica for Kinesiology Tape Products
March 18, 2026 06:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Announces Pricing of $60 Million Private Placement

Proceeds expected to support expansion of next-generation GABA-aminotransferase inhibitor, OV329, into tuberous sclerosis complex and infantile spasmsFinancing led by Point72 with participation from...
March 17, 2026 17:01 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations and four cancer types, including first evidence of activity in gastric...
March 17, 2026 16:05 ET | Source: Longeveron

Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

Longeveron reported financial results for the year ended December 31, 2025 and provided a business update. Results from pivotal P2 trial anticipated 3Q26.
March 17, 2026 08:25 ET | Source: Polyrizon Ltd.

Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program

Raanana, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated...
March 13, 2026 14:45 ET | Source: Tevogen Bio Inc

Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization

Tevogen highlights capital discipline, minimal share use, strong insider ownership, and potential acquisitions while exploring ways to reflect asset value
March 12, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy

Conventional chemo hits walls of resistance, brutal toxicity, and minimal progress. PRP changes the game.
March 12, 2026 02:00 ET | Source: Pharming Group N.V.

Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow

Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow
March 11, 2026 09:15 ET | Source: Psyence Biomedical Ltd.

Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone

NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today reinforced how its strategic investment in PsyLabs strengthens its...